Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study
N/A
12 Years
N/A
12 Years
N/A
Open (Enrolling by invite only)
Both
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Both
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Trial Information
Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study
Inclusion Criteria:
1. Enrollment in the RAVE trial
2. Completion of RAVE Common Closeout Date visit
3. Informed consent
Exclusion Criteria:
1. Refusal to participate
2. Inability to comply with standard-of-care, including routine clinical visits and
testing.
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Long-term safety of rituximab for the treatment of ANCA-associated vasculitis
Outcome Description:
To determine the long-term safety of rituximab for the treatment of ANCA-associated vasculitis (granulomatosis with polyangiitis (Wegener's granulomatosis) and microscopic polyangiitis).
Outcome Time Frame:
Four years
Safety Issue:
Yes
Authority:
United States: Institutional Review Board
Study ID:
ML27815
NCT ID:
NCT01586858
Start Date:
May 2012
Completion Date:
Related Keywords:
- Granulomatosis With Polyangiitis
- Microscopic Polyangiitis
- Vasculitis
- ANCA
- Rituximab
- Small vessel vasculitis
- Vasculitis
- Wegener Granulomatosis
- Systemic Vasculitis
- Microscopic Polyangiitis
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Name | Location |
|---|---|
| Johns Hopkins University | Baltimore, Maryland 21205 |
| University of Alabama | Birmingham, Alabama |
| Boston University | Boston, Massachusetts 02118 |
| Duke University | Durham, North Carolina 27710 |
| Hospital for Special Surgery | New York, New York 10021 |
| The Cleveland Clinic | Cleveland, Ohio 44195 |
| Mayo Clinic Foundation | Rochester, Minnesota 55905 |
